Khảo sát sự kháng kháng sinh của staphyloccus aureus và các chủng staphylococcus spp tại bệnh viện nhân dân gia định

berg’s Medical Microbiology, Mc Graw Hill.
42. Herwaldt L.A., Wenzel R.P (1995), “Dynamics of Hospital – Acquired
Infection”, Manual of Clinical Microbiology, Ampress-Washington DC, p.169176.
43. Hiramatsu K, Cui L, Kuroda M, Ito T (2001), The emergence and evolution of
methicillin-resistant Staphylococcus aureus, Trends Microbiol, 9:486-493.
44. Huang YC, Su LH, Wu TL, Lin TY (2006), Changing molecular epidemiology
of methicillin-resistant Staphylococcus aureus bloodstream isolates from a
teaching hospital in Northern Taiwan. J Clin Microbiol, 44:2268-2270.
45. Jain A, Agarwal J, Bansal S (2004), Prevelance of methicillin-resistant,
coagulase-neagative Staphylococci in neonatal intensive care units; finding
from a tertiary care hospital in India, J. Med Microbiol, 53:941-944.
46. Jawetz, Welnick, Adelberg’s, Medical microbiology 24th edition 2007, p.161P

P

196.
47. Jean F.MacFaddin (2000), Biochemical Tests for Identification of Medical
Bacteria, Lippincott Williams & Wilkins.
48. Joseph E. Rubin, Katherine R. Ball, Manuel Chirino-Trejo (2011),
Antimicrobial susceptibility of Staphylococcus aureus and Staphylococcus
pseudintermedius isolated from various animals, Can Vet J; 52:153–157.
49. Klevens, R. M., M. A. Morrison, J. Nadle, S. Petit, K. Gershman, S. Ray, L. H.
Harrison, R. Lynfield, G. Dumyati, J. M. Townes, A. S. Craig, E. R. Zell, G. E.
Fosheim, L. K. McDougal, R. B. Carey, and S. K. Fridkin, (2007), Invasive
methicillin-resistant Staphylococcus aureus infections in the United States.
JAMA 298:1763–1771.


92

50. Knauer A, Fladerer P, Strempfl C, Krause R, Wenisch C (2004): Effect of

hospitalization and antimicrobial therapy an

antimicrobial resistance of

colonizing Staphylococcus epidermidis. Wien Klin Wochenschr, 116(14):489494.
51. “Methicillin resistant Staphylococcus Aureus” Communicable Disease
Epidemiology and immunization Section, Public health, Seattle & King
country.
52. “Methicillin resistant Staphylococcus Aureus” Developed through a partnership
of The Ohio State University Medical Center, Mount Carmel Health,
OhioHealth and Nationwide Children’s Hospital, Columbus, Ohio (2008)
53. “Methicillin resistant Staphylococcus Aureus”, HealthLinkBC,

British

Columbia, Vietnamese number 73, 2005.
54. Miller LG, Diep BA (2008), Colonization, fomites, and virulence: rethinking the
pathogenesis of community-associated methicillin-resistant Staphylococcus
aureus infection. Clin Infect Dis; 46: 452–60.
55. NCCLS. Performance Standards for Antimicrobial susceptibility testing;
Fourteenth Informational Supplement. M100-S14 Vol. 24 No. 1. 2004.
56. Olusegun O. Soge, John S. Meschke, David B. No and Marilyn C. Roberts
(2009), Characterization of methicillin-resistant Staphylococcus aureus and
methicillin-resistant coagulase-negative Staphylococcus spp. isolated from US
West Coast public marine beaches, Journal of Antimicrobial Chemotherapy,
64, 1148–1155.
57. Patrick R.Muray, Manual of Clinical Microbiology, AMS Press Washington
DC, Sxth edition, p.1308.
58. Shittu AO, Nübel U, Udo EE, Lin J, Gaogakwe S (2009), Characterization of
methicillin-resistant Staphylococcus aureus (MRSA) isolates from hospitals in

KwaZulu-Natal (KZN) province, Republic of South Africa, J Med Microbiol,
58:1219-1226.


93

59. Siberry GK, Tekle T, Carroll K, Dick J (2003), Failure of clindamycin treatment
of

methicillin-resistant

Staphylococcus

aureus

expressing

inducible

clindamycin resistance in vitro. Clin Infect Dis, 37:1257–1260.
60. Sola C, Cortes P, Saka HA, Vindel A, Bocco JL (2006), Evolution and
molecular characterization of methicillin-resistant Staphylococcus aureus
epidemic and sporadic clones in Cordoba, Argentina, J Clin Microbiol, 44:192200.
61. Tiemersma EW, Bronzwaer SL, Lyytikainen O, Degener JE, Schrijnemakers P,
Bruinsma N, Monen J, Witte W, Grundman H (2004), European Antimicrobial
Resistance

Surveillance

System

Participants:

Methicillin-resistant

Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis, 10:1627-1634.
62. Yeliz Genc, Resit Ozkanca, Yunus Bekdemir (2008), Antimicrobial activity of
some sulfonamide derivatives on clinical isolates of Staphylococus aureus,
Annals of Clinical Microbiology and Antimicrobials, 7:17.


PHỤ LỤC
1. Các tiêu chuẩn giải thích đường kính vịng vô khuẩn ở Staphylococci
Kháng sinh
Penicillin
Penicillin
Oxacillin

Ampicillin
Methicillin
Nafcillin
Hợp chất β-lactam -chất
ức chế β-lactamase
Amoxicillin/clavulanic.a
Ampiccillin-sulbactam
Piperacillin-tazobactam
Ticarcillin-clavulanic.a
Cephems (đường chích)
Cefamandole
Cefazolin

Cefepime
Cefmetazole
Cefonicid
Cefoperazone
Cefotaxime
Cefotetan
Ceftazidime
Ceftizoxime
Ceftriaxone
Cefuroxime sodium
(parenteral)
Cephalothin
Moxalactam
Cephems (đường uống)
Cefaclor
Cefdibir
Cefpodoxime
Cefprozil
Cefuroxime axetil
(uống)
Loracarbef

Nồng độ đĩa
kháng sinh

Đường kính vịng vơ khuẩn
S
I
R

10 đơn vị
30 μg cefoxitin
1 μg oxacillin
30 μg cefoxitin
1 μg oxacillin
10 μg
5 μg
1 μg

≤ 28
≤ 21
≤ 10
≤ 24
≤ 17
≤ 28
≤9
≤ 10

11 - 12
10 - 13
11 - 12

≥ 29
≥ 22
≥ 13
≥ 25
≥ 18
≥ 29
≥ 14
≥ 13

20/10 μg
10/10 μg
100/10 μg
75/10 μg

≤ 19
≤ 11
≤ 17
≤ 22

12 – 14
-

≥ 20
≥ 15
≥ 18
≥ 23

30 μg
30 μg
30 μg
30 μg
30 μg
75 μg
30 μg
30 μg
30 μg
30 μg
30 μg

30 μg

≤ 14
≤ 14
≤ 14
≤ 12
≤ 14
≤ 15
≤ 14
≤ 12
≤ 14
≤ 14
≤ 13
≤ 14

15 – 17
15 – 17
15 – 17
13 – 15
15 – 17
16 – 20
15 – 22
13 – 15
15 – 17
15 – 19
14 – 20
15 – 17

≥ 18
≥ 18

≥ 18
≥ 16
≥ 18
≥ 21
≥ 23
≥ 16
≥ 18
≥ 20
≥ 21
≥ 18

30 μg
30 μg

≤ 14
≤ 14

15 – 17
15 – 22

≥ 18
≥ 23

30 μg
5 μg
10 μg
30 μg
30 μg

≤ 14

≤ 16
≤ 17
≤ 14
≤ 14

15 – 17
17 – 19
18 – 20
15 – 17
15 – 22

≥ 18
≥ 20
≥ 21
≥ 18
≥ 23

30 μg

≤ 14

15 – 17

≥ 18


Carbapenems
Ertapenem
Imipenem
Meropenem

Glycopepides
Vancomycin
Teicoplanin
Aminoglycosides
Gentamicin
Amikacin
Kanamicin
Netilmicin
Tobramicin
Macrolides
Azithromycin or
Clarithromycin or
Erythromycin
Ketolides
Telithromycin
Tetracyclines
Tetracycline
Doxycycline
Minocycline
Fluoroquinolones
Ciprofloxacin or
Gatifloxacin
Levofloxacin
Ofloxacin
Moxiloxacin
Lomefloxacin
Norfloxacin
Enoxacin
Grepafloxacin
Sparfloxacin

Fleroxacin
Nitrofurantoins
Nitrofurantoin
Lincosamides
Clindamycin

10 μg
10 μg
10 μg

≤ 15
≤ 13
≤ 13

16 – 18
14 – 15
14 – 15

≥ 19
≥ 16
≥ 16

30 μg
30 μg

≤ 10

11 – 13

≥ 15

≥ 14

10 μg
30 μg
30 μg
30 μg
10 μg

≤ 12
≤ 14
≤ 13
≤ 12
≤ 12

13 – 14
15 – 16
14 – 17
13 – 14
13 – 14

≥ 15
≥ 17
≥ 18
≥ 15
≥ 15

15 μg
15 μg
15 μg

≤ 13
≤ 13
≤ 13

14 – 17
14 – 17
14 – 22

≥ 18
≥ 18
≥ 23

15 μg

≤ 18

19 – 21

≥ 22

30 μg
30 μg
30 μg

≤ 14
≤ 12
≤ 14

15 – 18
13 – 15

15 – 18

≥ 19
≥ 16
≥ 19

5 μg
5 μg
5 μg
5 μg
5 μg
10 μg
10 μg
10 μg
5 μg
5 μg
5 μg

≤ 15
≤ 19
≤ 15
≤ 14
≤ 20
≤ 18
≤ 12
≤ 14
≤ 14
≤ 15
≤ 15

16 – 20
20 – 22
16 – 18
15 – 17
21 – 23
19 – 21
13 – 16
15 – 17
15 – 17
16 – 18
16 – 18

≥ 21
≥ 23
≥ 19
≥ 18
≥ 24
≥ 22
≥ 17
≥ 18
≥ 18
≥ 19
≥ 19

300 μg

≤ 14

15 – 16

≥ 17

2 μg

≤ 14

15 – 20

≥ 21


Các chất ức chế con
đường biến dưỡng folate
1.25/
≤ 10
Trimethoprim/
23.75 μg
Sulfamethoxazole
250 or 300 μg
≤ 12
Sulfonamides
Trimethoprim
5 μg
≤ 10
Phenicols
Chloramphenicol
30 μg
≤ 12
Ansamycins
Rifampin

5 μg
≤ 16
Streptogramins
Quinupristin-dalfopristin
15 μg
≤ 15
Oxazolidinones
Linezolid
30 μg
Ghi chú: S (susceptible): nhạy cảm; I (intermediate): trung
kháng

11 – 15

≥ 16

13 – 16
11 – 15

≥ 17
≥ 16

13 – 17

≥ 18

17 – 19

≥ 20

16 – 18

≥ 19

≥ 21
gian; R (resistant): đề